Arrowhead Pharmaceuticals released early clinical data showing its RNAi candidates, including ARO‑INHBE, produced meaningful fat reductions when used with Eli Lilly’s tirzepatide (Zepbound). In small cohorts, the combination doubled weight loss and produced substantial reductions in visceral and liver fat versus tirzepatide alone, supporting adipose delivery proof‑of‑concept for Arrowhead’s platform. The company plans to push multiple RNAi obesity programs into later‑stage testing, and these results are likely to intensify competition in long‑acting and gene‑silencing approaches to obesity. Arrowhead’s data also triggered investor interest and may shape partnering and financing activity in the obesity therapeutics space.